AU2004285436C1 - Composition and dosage form for sustained effect of levodopa - Google Patents

Composition and dosage form for sustained effect of levodopa Download PDF

Info

Publication number
AU2004285436C1
AU2004285436C1 AU2004285436A AU2004285436A AU2004285436C1 AU 2004285436 C1 AU2004285436 C1 AU 2004285436C1 AU 2004285436 A AU2004285436 A AU 2004285436A AU 2004285436 A AU2004285436 A AU 2004285436A AU 2004285436 C1 AU2004285436 C1 AU 2004285436C1
Authority
AU
Australia
Prior art keywords
levodopa
dopamine
inhibitor
hours
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004285436A
Other languages
English (en)
Other versions
AU2004285436A1 (en
AU2004285436B2 (en
Inventor
Moshe Flashner-Barak
E. Itzhak Lerner
Vered Rosenberger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of AU2004285436A1 publication Critical patent/AU2004285436A1/en
Application granted granted Critical
Publication of AU2004285436B2 publication Critical patent/AU2004285436B2/en
Publication of AU2004285436C1 publication Critical patent/AU2004285436C1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2004285436A 2003-10-20 2004-10-14 Composition and dosage form for sustained effect of levodopa Ceased AU2004285436C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51297303P 2003-10-20 2003-10-20
US60/512,973 2003-10-20
PCT/US2004/034121 WO2005042101A1 (en) 2003-10-20 2004-10-14 Composition and dosage form for sustained effect of levodopa

Publications (3)

Publication Number Publication Date
AU2004285436A1 AU2004285436A1 (en) 2005-05-12
AU2004285436B2 AU2004285436B2 (en) 2009-01-08
AU2004285436C1 true AU2004285436C1 (en) 2009-07-16

Family

ID=34549241

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004285436A Ceased AU2004285436C1 (en) 2003-10-20 2004-10-14 Composition and dosage form for sustained effect of levodopa

Country Status (11)

Country Link
US (1) US20050113452A1 (enExample)
EP (1) EP1675651A1 (enExample)
JP (1) JP2007509146A (enExample)
KR (2) KR100894465B1 (enExample)
AU (1) AU2004285436C1 (enExample)
CA (1) CA2553156A1 (enExample)
EA (1) EA200600626A1 (enExample)
IL (1) IL174591A0 (enExample)
MX (1) MXPA06004327A (enExample)
NZ (1) NZ546662A (enExample)
WO (1) WO2005042101A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7674480B2 (en) 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
DE10214188B4 (de) 2002-03-28 2005-08-25 Siemens Ag Verfahren zur gesicherten Übertragung von Daten, insbesondere zur Übertragung über eine Luftschnittstelle
US20070191815A1 (en) 2004-09-13 2007-08-16 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery
KR20070036797A (ko) * 2004-07-26 2007-04-03 테바 파마슈티컬 인더스트리즈 리미티드 장용 코팅된 중심정을 갖는 제형
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
US20070027216A1 (en) * 2005-07-15 2007-02-01 Bridget Larson Novel hydrochloride salts of levodopa
EP1945188A2 (en) * 2005-11-07 2008-07-23 Teva Pharmaceutical Industries Ltd. Levodopa compositions
RU2484815C2 (ru) * 2006-05-31 2013-06-20 Зольвай Фармасьютиклз Гмбх Продолжительное 24-часовое введение в кишечник леводопа/карбидопа
US8765178B2 (en) 2006-07-19 2014-07-01 Watson Laboratories, Inc. Controlled release formulations and associated methods
ES2521494T3 (es) * 2007-04-02 2014-11-12 Parkinson's Institute Métodos y composiciones para la reducción de los efectos secundarios de tratamientos terapéuticos
US20130017259A1 (en) 2011-07-06 2013-01-17 The Parkinson's Institute Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients
WO2016123406A1 (en) 2015-01-28 2016-08-04 Chrono Therapeutics Inc. Drug delivery methods and systems
EP3267875A4 (en) 2015-03-12 2018-12-05 Chrono Therapeutics Inc. Craving input and support system
WO2018129304A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
CA3101966A1 (en) 2018-05-29 2019-12-05 Morningside Venture Investments Limited Drug delivery methods and systems
US12397141B2 (en) 2018-11-16 2025-08-26 Morningside Venture Investments Limited Thermally regulated transdermal drug delivery system
IT202000019303A1 (it) * 2020-08-05 2022-02-05 Univ Degli Studi Di Brescia Analoghi strutturali del metilfenidato come agenti disease-modifying della malattia di parkinson
EP4316482A1 (en) * 2022-08-01 2024-02-07 4P-Pharma Levodopa for preventing addiction

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994392A (en) * 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
WO2002000213A1 (en) * 2000-06-23 2002-01-03 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US6797283B1 (en) * 1998-12-23 2004-09-28 Alza Corporation Gastric retention dosage form having multiple layers

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2042520T3 (es) * 1986-06-10 1993-12-16 Chiesi Farma Spa Composiciones farmaceuticas que contienen el ester metilico de levodopa, preparacion y aplicaciones terapeuticas del mismo.
US4832957A (en) * 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
US4983400A (en) * 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
ZA889189B (en) * 1986-06-16 1989-08-30 Merck & Co Inc Controlled release combination of carbidopa/levodopa
US4716246A (en) * 1986-08-22 1987-12-29 Merck & Co., Inc. Process for L-dopa
US5041430A (en) * 1989-09-18 1991-08-20 Du Pont Mereck Pharmaceutical Company Oral anticoagulant/platelet inhibitor low dose formulation
US5607969A (en) * 1992-12-24 1997-03-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem L-DOPA ethyl ester to treat Parkinson's disease
US6117453A (en) * 1995-04-14 2000-09-12 Pharma Pass Solid compositions containing polyethylene oxide and an active ingredient
US5840756A (en) * 1995-07-21 1998-11-24 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition of L-DOPA ester
US6235311B1 (en) * 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
US7674480B2 (en) * 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
AU2002320360B2 (en) * 2001-07-10 2005-05-26 Teva Pharmaceutical Industries Ltd. Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery
US20040052843A1 (en) * 2001-12-24 2004-03-18 Lerner E. Itzhak Controlled release dosage forms
NZ552514A (en) * 2001-12-24 2008-08-29 Teva Pharma Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994392A (en) * 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
US6797283B1 (en) * 1998-12-23 2004-09-28 Alza Corporation Gastric retention dosage form having multiple layers
WO2002000213A1 (en) * 2000-06-23 2002-01-03 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Camicioli et al., Clinical Neuropharmacology, July 2001, Vol 24, No 4, pp 208-213 *
Chouza et al., Acta Neurologica Scandinavica Supplementum, 1989, Vol 126, pp 127-137 *
Frackiewicz et al., Annals of Pharmacotherapy, February 2002, Vol 36, pp 225-230 *
Pearce et al., Movement Disorders Official Journal of the Movement Disorder Society, September 2002, Vol 17, No 5, pp 877-886 *

Also Published As

Publication number Publication date
MXPA06004327A (es) 2007-01-26
KR100894465B1 (ko) 2009-04-22
US20050113452A1 (en) 2005-05-26
CA2553156A1 (en) 2005-05-12
EA200600626A1 (ru) 2007-02-27
IL174591A0 (en) 2006-08-20
KR20070085032A (ko) 2007-08-27
WO2005042101A8 (en) 2006-10-19
EP1675651A1 (en) 2006-07-05
AU2004285436A1 (en) 2005-05-12
NZ546662A (en) 2009-03-31
JP2007509146A (ja) 2007-04-12
AU2004285436B2 (en) 2009-01-08
WO2005042101A1 (en) 2005-05-12
KR20080109101A (ko) 2008-12-16

Similar Documents

Publication Publication Date Title
AU2004285436B2 (en) Composition and dosage form for sustained effect of levodopa
US12521363B2 (en) Use of levodopa, carbidopa and entacapone for treating Parkinson's disease
Nyholm Pharmacokinetic optimisation in the treatment of Parkinson’s disease: an update
JP7534354B2 (ja) 朝の無動状態を治療するための拍動性薬物送達系
EP2623099A1 (en) Composition and method for treating neurological disease
EP3684344B1 (en) Delayed release deferiprone tablets and methods of using the same
EP1814529B1 (en) Dosage form time-lagged of drugs for the therapy of insomnia
JP2003513038A (ja) ホスホジエステラーゼ４阻害剤の投与法
US20220211641A1 (en) Composition and method for treating neurological disease
US20070178149A1 (en) Levodopa compositions
CN118871096A (zh) 包含l-色氨酸、l-5-羟基色氨酸和外周降解抑制剂的药物组合物和药物
MXPA06014463A (es) Composicion farmaceutica que contiene una combinacion de antiespasmodico y analgesico y su uso.

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 27 FEB 2009.

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 27 FEB 2009

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired